Buy Cibinqo 50 mg/1 abrocitinib

Cibinqo 50 mg tablets contain abrocitinib, a medication used to manage certain inflammatory conditions. This oral treatment is designed to help alleviate symptoms and improve quality of life for eligible patients.

Strength

50 mg/1

Pack Size

30 TABLET, FILM COATED in 1 BOTTLE (0069-0235-30)

Manufacturer / TM Owner

Pfizer Laboratories Div Pfizer Inc

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Cibinqo 50 mg tablets are primarily used for the treatment of moderate to severe atopic dermatitis in adults. This medication works by targeting specific pathways involved in inflammation, helping to reduce symptoms such as itching and skin lesions. Patients often wonder, 'What is Cibinqo used for?' and the answer lies in its ability to manage chronic skin conditions effectively.

Side Effects

Common effects of Cibinqo 50 mg tablets may include nausea, dizziness, and headache. Some users might experience fatigue or upper respiratory tract infections. These effects vary among individuals and are not exhaustive. Always consult a healthcare provider for personalized advice.

Precautions & Warnings

Cibinqo 50 mg tablets should be handled with care, especially by individuals with a history of infections or immune system disorders. It is important to follow the prescribed dosage and monitor for any adverse reactions. Store the medication as directed to maintain its efficacy.

Avoid Interactions

Cibinqo 50 mg tablets may interact with other medications, including those that affect the immune system or liver enzymes. Alcohol consumption should be discussed with a healthcare provider, as it may influence the medication's effects. Always inform your healthcare provider about all medications you are taking.

References

Frequently Asked Questions

Cibinqo 50 mg tablets are used to manage moderate to severe atopic dermatitis in adults by targeting inflammation.

Cibinqo 50 mg tablets are taken orally, typically once daily, as directed by a healthcare provider.

Common side effects may include nausea, dizziness, headache, fatigue, and upper respiratory tract infections.

Cibinqo may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Store Cibinqo 50 mg tablets at room temperature, away from moisture and heat, as directed on the packaging.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.